Our studies in cancer biology and pediatric oncology are focused on cellular plasticity, a phenomenon that relates both to the fundamental mechanisms of cancer pathogenesis and to the development of improved rational therapies. Detailed information about our research is available at http://alexkentsis.net.
Alex Kentsis, MD, PhD
Research FocusCancer biologist and pediatric oncologist Alex Kentsis leads research in the functional proteomics and molecular pharmacology of refractory childhood cancers.
- MD, Mount Sinai School of Medicine
- PhD, New York University
- Ortiz MV, Ahmed S, Burns M, Henssen AG, Hollmann TJ, MacArthur I, Gunasekera S, Gaewsky L, Bradwin G, Ryan J, Letai A, He Y, Naranjo A, Chi YY, LaQuaglia M, Heaton T, Cifani P, Dome JS, Gadd S, Perlman E, Mullen E, Steen H, Kentsis A. Prohibitin is a prognostic marker and therapeutic target to block chemotherapy resistance in Wilms’ tumor. JCI Insight, 2019
- Ser Z, Cifani P, Kentsis A. Optimized cross-linking mass spectrometry for in situ interaction proteomics. J Proteome Research, 2019
- Pershing Square Sohn Prize, Leukemia & Lymphoma Society Scholar Award (2019), St. Baldrick’s Robert J. Arceci Innovation Award, Elected Member of American Society for Clinical Investigation, Society for Pediatric Research Young Investigator Award (2018), Rita Allen Foundation Scholar Award, Damon Runyon Cancer Research Foundation Clinical Investigator Award (2016), American Society of Hematology Scholar Award (2014), Burroughs Wellcome Fund Career Award for Medical Scientists (2013)
- Pediatric Hematology-Oncology Fellowship, Dana-Farber Cancer Institute, Residency in Pediatrics, Boston Children’s Hospital, Harvard Medical School
- MD, PhD, Mount Sinai School of Medicine and New York University
- AB, SM, University of Chicago